Table 2.

Comorbidities and therapies of study cohort^a

Factors	ULT (n = 2690)	No ULT (n = 10,061)	CKD Stage 2 (n = 4343)	CKD Stage 3 (n = 6299)	CKD Stage 4 (n = 2109)
CV-related disease	51	46	32	52	63
Diabetes	50	47	36	51	62
Dyslipidemia	86	85	78	88	91
Hypertension	95	92	85	96	98
Obesity (BMI < 30 kg/m2)	48	46	49	45	43
Osteoarthritis	46	42	37	47	43
Rheumatoid arthritis	4	3	2	3	4
Gout diagnosis at index date	47	24	33	30	20
Corticosteroids	52	49	48	50	49
Colchicine	17	9	11	11	9
NSAIDs	82	79	83	80	74
ULT prescription
Allopurinol	97	NA	29	55	16
Febuxostat	2		7	57	36
Probenecid	1		52	48	0

^aData are presented as percentages. Some percentages may not total to 100 because patients had more than 1 comorbidity or treatment.

BMI = body mass index; CKD = chronic kidney disease; CV = cardiovascular; NA = not applicable; NSAIDs = nonsteroidal anti-inflammatory drugs; ULT = urate-lowering therapy.